PLAQUE PSORIASIS

This study tested a new drug called LY4100511 to see if it is safe and effective for treating adults with moderate-to-severe plaque psoriasis. Researchers compared different doses of the drug against a placebo in 222 participants. The main goal was to see how many people achieved…

This study tested an investigational oral medication called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. It involved 255 participants who took different doses of the drug or a placebo for 16 weeks. The main goal was to see how well the drug cleared skin plaqu…

This study observed how well and how safely a medication called QLETLI worked for children and teenagers with severe plaque psoriasis. It followed 80 young patients in China for about 24 weeks to see if their skin cleared up. The goal was to gather real-world information on this …

This study tested an investigational drug called TQH3906 in 209 adults with moderate-to-severe plaque psoriasis. The main goal was to see if the drug safely reduces the severity of skin plaques and improves patients' quality of life over 12 weeks. Researchers measured how much sk…

This study looked at how satisfied adults with mild-to-moderate scalp psoriasis were with a prescription cream called Wynzora®. Researchers followed 291 people for 12 weeks in a real-world setting to see how the cream worked, how it affected their quality of life and itch, and ho…

This large, late-stage study tested whether a new oral drug, TAK-279, could clear or nearly clear the thick, scaly skin patches of moderate-to-severe plaque psoriasis. Over 1,100 participants were randomly assigned to receive TAK-279, a placebo (inactive pill), or an already-appr…

This study tested whether the drug guselkumab is safe and effective for treating moderate-to-severe plaque or scalp psoriasis specifically in people with skin of color. It involved 213 participants who identified as non-white or non-Caucasian. The main goal was to see if the drug…

This first-in-human study tested the safety and how the body processes CAN10, a new antibody being developed for plaque psoriasis. The trial involved 80 healthy volunteers and people with mild to moderate psoriasis, testing single and repeated doses. Researchers monitored side ef…

This completed Phase 2 study tested an experimental oral medication called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The goal was to see if the pill could safely reduce the severity of skin plaques and improve patients' quality of life. Participants were ra…

This study tested whether doubling the dose of the drug TA-650 could help patients with moderate-to-severe psoriasis who initially responded to a standard dose but later saw their symptoms return. The trial involved 51 adults with different forms of psoriasis, including plaque ps…

This study tested a new oral drug called TAK-279 for people with moderate-to-severe plaque psoriasis. About 693 participants were randomly assigned to receive TAK-279, a placebo (inactive pill), or an existing approved drug for comparison. The main goal was to see how well TAK-27…

This study tested a new topical ointment called SGX302, which is activated by visible light, to see if it could improve skin lesions in people with mild-to-moderate plaque psoriasis. Fifteen participants applied the treatment to their skin for an 18-week course. The main goal was…

This study tested whether a pill called apremilast could help control moderate-to-severe plaque psoriasis in Chinese adults. Over 200 participants were randomly assigned to receive either the real drug or a placebo pill for 16 weeks. Researchers measured how much the drug improve…

This study tested a new oral medication called AX-158 for people with mild to moderate plaque psoriasis. For 28 days, 31 participants took either the drug or a placebo pill, followed by a safety check for another month. The main goal was to see if the drug was safe and well-toler…

This study tested whether an investigational drug called D-2570 is effective and safe for treating moderate-to-severe plaque psoriasis. It involved 161 participants who were randomly assigned to receive either D-2570 or a placebo (a dummy treatment) for 12 weeks. The main goal wa…

This study followed 331 adults with moderate-to-severe plaque psoriasis who were already using or starting the drug tildrakizumab (Ilumetri®) as part of their regular care. The goal was to see how well the treatment worked and how safe it was over nearly two years in a real-world…

This study tested an investigational oral medication, JNJ-77242113, to see how well it controls moderate-to-severe plaque psoriasis over a longer period. It involved 227 people who had already completed a prior 16-week study with the same drug. The main goal was to measure how ma…

This study tested whether an artificial intelligence (AI) tool could help doctors diagnose skin conditions more accurately, especially rare ones like generalized pustular psoriasis. Fifteen doctors reviewed 100 patient images, first giving their own diagnosis and then seeing the …

This study tested whether an artificial intelligence (AI) tool could help primary care doctors more accurately diagnose various skin conditions, including skin cancers like melanoma. Nine doctors reviewed 30 skin images, first giving their own diagnosis and then reviewing the AI'…

This study tested whether digital photographs could be used to reliably measure the severity of plaque psoriasis from a distance, compared to a traditional in-person doctor's exam. About 34 adults with plaque psoriasis participated. They had their skin condition assessed in perso…

This study looked at whether switching patients to a higher concentration version of the drug adalimumab (brand name SIMLANDI™) causes less injection site pain than the standard version. It involved 324 adults in Canada who were already using adalimumab for conditions like Crohn'…